What is he best known for?
The fields of study he is best known for:
His primary scientific interests are in Antibody, Virology, Epitope, Glycoprotein and Binding site.
His Antibody research incorporates themes from Molecular biology, Immune system, Antigen and Cell biology.
His study in Virology is interdisciplinary in nature, drawing from both Immunoglobulin G and Immunology.
His studies deal with areas such as Viral envelope and Conserved sequence as well as Epitope.
His Glycoprotein research includes themes of Biophysics, Viral entry and Peptide sequence.
Richard T. Wyatt interconnects Protein structure, Receptor and Conformational change in the investigation of issues within Binding site.
His most cited work include:
- Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody (2646 citations)
- The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. (1424 citations)
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 (1410 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Virology, Antibody, Glycoprotein, Epitope and Binding site.
The Virology study combines topics in areas such as Immunogen and Immunology.
His Antibody research incorporates elements of Molecular biology, Immune system and Antigen.
Richard T. Wyatt combines subjects such as V3 loop, Glycosylation and Cell biology with his study of Molecular biology.
His Glycoprotein research includes elements of Biophysics, Plasma protein binding, Gp41 and Immunogenicity.
His Epitope research incorporates themes from Viral envelope, Envelope glycoprotein GP120, Viral entry, Glycan and Protein structure.
He most often published in these fields:
- Virology (81.20%)
- Antibody (71.60%)
- Glycoprotein (59.20%)
What were the highlights of his more recent work (between 2014-2021)?
- Virology (81.20%)
- Antibody (71.60%)
- Glycoprotein (59.20%)
In recent papers he was focusing on the following fields of study:
Richard T. Wyatt mainly investigates Virology, Antibody, Glycoprotein, Epitope and Immunogen.
In the field of Virology, his study on Neutralization overlaps with subjects such as Trimer.
Richard T. Wyatt has researched Antibody in several fields, including Vaccination, Binding site and Glycan.
His study in Glycoprotein is interdisciplinary in nature, drawing from both HIV vaccine, Gp41, Furin and Stereochemistry.
His studies link Heterologous with Epitope.
His Monoclonal antibody research integrates issues from Molecular biology, Plasma protein binding and B-cell receptor.
Between 2014 and 2021, his most popular works were:
- Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. (174 citations)
- Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. (146 citations)
- Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site (105 citations)
In his most recent research, the most cited papers focused on:
Richard T. Wyatt mainly focuses on Virology, Glycoprotein, Antibody, Glycan and Epitope.
His work on Neutralization is typically connected to Trimer as part of general Virology study, connecting several disciplines of science.
His Glycoprotein study combines topics from a wide range of disciplines, such as Germinal center, Gp41 and Furin.
His studies in Antibody integrate themes in fields like Virus, Plasma protein binding and Molecular biology.
His work in Molecular biology covers topics such as Complementarity determining region which are related to areas like Protein structure.
His work carried out in the field of Neutralizing antibody brings together such families of science as Titer, T cell, Cell-mediated cytotoxicity, Vaccination and Binding site.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
